While the current management may be very astute at carrying out research and developing potentially great drug/drug platforms, they ARE NOT showing any signs of success when it comes to commercialisation of these products.
Could explain why HQ haven't been able to strike a DEP® Cabazitaxel and DEP® Docetaxel license deal to date - they may not be up to the challenge or perhaps the results perused under an NDA by multiple pharma groups don't stack up ?
How can a company tout consistently over the years that they are in 'confidential commercial negotiations with several potential partners' and come up empty handed year after year ? They claim these negotiations are ongoing in most ASX announcements - here's an example from 2021 off the back of the interim phase 2 DEP® Cabazitaxel clinical trial results
Looking like another week of absolutely nothing coming out of Starpharma again as another Friday is upon us .... not even a further update on AACR 2 days in as some hoped earlier in the week
Poster Session A on Thursday, October 12, from 12:30-4 P.M.
Poster Session B on Friday, October 13, from 12:30-4 P.M
Poster Session C on Saturday, October 14 from 12:30-4 P.M.
- Forums
- ASX - By Stock
- Expectations for September
While the current management may be very astute at carrying out...
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.00M |
Open | High | Low | Value | Volume |
9.8¢ | 10.5¢ | 9.6¢ | $210.8K | 2.098M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30408 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 3523 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30408 | 0.095 |
2 | 15638 | 0.094 |
3 | 83394 | 0.093 |
2 | 108435 | 0.091 |
2 | 41000 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 3523 | 2 |
0.105 | 119848 | 4 |
0.110 | 114099 | 6 |
0.115 | 77331 | 6 |
0.120 | 89055 | 5 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |